1 Comments
- inactive, on 08/02/2008, -0/+3Now to get this test on every single patient before they start statins would not be cost-effective unless it is incredibly cheap.
-
Add a Comment
reuters.com — The House Energy and Commerce committee wants the U.S. Food and Drug Administration to turn over the results of an analysis about the potential links between cancer and cholesterol drug Vytorin.